Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives $16.11 Average PT from Brokerages
Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report) has been assigned an average rating of “Moderate Buy” from the nine research firms that are covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective […]